Wision A.I.
Wision A.I. is a Shanghai-based medical device company that develops regulatory-cleared deep-learning CAD software for gastrointestinal endoscopy (EndoScreener) and histopathology (PathoCruz), selling directly to hospitals and clinical laboratories via medical device licensing.
- Company typePrivate
- Founded2016
- HeadquartersShanghai, China
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What Wision A.I. does
Wision A.I. is a Shanghai-based medical device software company founded in 2016 that develops computer-aided diagnosis (CAD) algorithms for optical clinical imaging, with a stated focus on solving diagnostic problems using small datasets rather than the prevailing big-data paradigm. Its commercial portfolio consists of two flagship products: EndoScreener, a real-time AI-aided detection (CADe) tool that flags potential lesions and polyps during colonoscopy, and PathoCruz, which localizes cancerous regions in whole-slide histopathology images; a 3D reconstruction add-on, PathoCruz 3D, extends the pathology line into tumor spatial visualization. Underlying both products is a deep-learning computer-vision pipeline with an articulated mathematical-rigor orientation toward limited training data.
The company monetizes as a regulated medical device vendor, not as a SaaS or platform play. Its products have been cleared as medical devices across the three principal regulatory regimes — FDA 510(k) (K211326), CE-MDR Class II (the first colonoscopy CADe clearance under MDR 2017/745), and NMPA Class III via China's Innovative Medical Device Special Approval Procedure — all secured in August 2022. Wision A.I. goes to market through direct enterprise sales to hospitals, endoscopy centers, and pathology laboratories, with revenue structured around one-time medical-device software licensing rather than recurring subscription. The customer base is enterprise-clinical, segmented primarily by use case (gastroenterology/endoscopy versus histopathology), and the company maintains a modest operating footprint of 11–50 employees supported by a single disclosed $2.99M Series A from Northern Light Venture Capital in mid-2018.
Wision A.I. firmographics
Firmographics- Name
- Wision A.I.
- Legal name
- Wision A.I.
- Website
- https://wision.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Wision A.I. is a Shanghai-based medical device company that develops regulatory-cleared deep-learning CAD software for gastrointestinal endoscopy (EndoScreener) and histopathology (PathoCruz), selling directly to hospitals and clinical laboratories via medical device licensing.
- Ownership category
- akta.pro rank
Wision A.I. industry classification
Industry- Product category
- Medical Imaging AI Software
- NAICS
- Navigational, Measuring, Electromedical, and Control Instruments Manufacturing (3345)
- SIC
- Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Medical Imaging AI (HDAAAEAH)
- akta.pro secondary industries
- Radiology AI, CAD & Advanced Visualization Software (HLAHABAJ), Digital & AI-Enabled Diagnostics (algorithmic interpretation, decision support tied to assays) (HLAAALAO)
Keywords
Where Wision A.I. is headquartered
LocationHeadquarters
- HQ city
- Shanghai
- HQ country
- China
- HQ region
- Asia
Markets served
Wision A.I. business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Others
Revenue model
- Medical Device Software Licensing: Wision A.I. generates revenue through the sale of regulatory-cleared AI-assisted diagnostic software medical devices. Their products (EndoScreener, PathoCruz) are cleared as medical devices in multiple jurisdictions (FDA, CE-MDR, NMPA), suggesting a medical device licensing model.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
Wision A.I. product offering
Product offeringCore offering
Wision A.I. develops and sells regulatory-cleared Computer-Aided Diagnosis (CAD) software for clinical optical medical imaging. Its core products—EndoScreener for real-time AI-assisted gastrointestinal endoscopy and colonoscopy, and PathoCruz for cancer region localization in whole slide histopathology images (plus the PathoCruz 3D reconstruction module)—are built on deep learning algorithms optimized for small datasets and are licensed to hospitals, endoscopy centers, and pathology laboratories.
Product overview
Wision A.I. offers a portfolio of Computer-Aided Diagnosis (CAD) products for clinical medical imaging. The core offerings consist of EndoScreener (real-time AI diagnostics for GI endoscopy/colonoscopy) and PathoCruz (histopathology whole slide image analysis). PathoCruz 3D is an add-on module that extends PathoCruz with 3D reconstruction capabilities for visualizing tumor spatial characteristics. All products leverage deep learning algorithms optimized for small datasets.
Differentiator
Problem solved
Functional benefit
Brands
- EndoScreener: Realtime AI-aided diagnostics product for gastrointestinal endoscopy procedures.
- PathoCruz
Products and services
- EndoScreener Real-time AI-aided diagnostic software for gastrointestinal endoscopy procedures; provides computer-aided detection (CADe) during colonoscopy, automatically identifying and highlighting potential lesions, polyps, and adenomas. Regulatory-cleared as a medical device (FDA 510(k), CE-MDR Class II, NMPA Class III) and licensed to hospitals and endoscopy centers.
- PathoCruz AI-powered whole slide imaging analysis software for histopathology; performs automated localization of cancerous regions and tumor areas in Whole Slide Images (WSI) to support pathologists in cancer diagnosis. Targets clinical pathology laboratories and hospital pathology departments.
- PathoCruz 3D Automated histological 3D reconstruction module that visualizes tumor spatial characteristics from whole slide imaging data; extends the PathoCruz platform for advanced spatial tumor analysis by pathologists.
Quantifiable outcome
- First CE Mark Class II Certificate of CADe tools for colonoscopy under the new Medical Devices Regulation (MDR 2017/745)
Companies that use Wision A.I.
Customer profileSegments2 records
Ideal customer profiles2 records
Wision A.I. technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability3 records
Feature3 records
Wision A.I. partnerships and signals
Strategic signalScale indicators1 record
Recent moves5 records
Expansion highlights4 records
Wision A.I. competitors and assessment
Company assessmentDirect peers
- Iterative Health: US-based startup developing AI-driven computer-aided detection (CADe) and computer-aided diagnosis (CADx) tools for gastroenterology, most notably for colonoscopy. Direct competitor to Wision's EndoScreener product line in the GI endoscopy AI space.
- Cosmo Pharmaceuticals: Specialty pharma company that developed the AI CADe engine (Medtronic GI Genius) for colonoscopy. Direct peer in the colonoscopy AI algorithm category competing with EndoScreener's core clinical application.
- Paige.AI: US-based digital pathology AI company with FDA-authorized cancer detection algorithms for whole slide imaging. Direct competitor to Wision's PathoCruz product line in AI-enabled cancer localization on histopathology slides.
- Ibex Medical Analytics: Israel-based AI pathology company offering cancer detection and grading solutions for biopsy tissue across multiple tumor types. Direct peer to PathoCruz in the digital pathology AI market serving hospital pathology laboratories.
Broad incumbents
- Medtronic (GI Genius): Global medical device giant that markets GI Genius, an AI colonoscopy CADe system acquired through its partnership with Cosmo Pharmaceuticals. Broad incumbent competitor offering Wision's primary GI endoscopy use case bundled into a vast medtech portfolio.
- Olympus: Dominant endoscope manufacturer increasingly integrating AI features (e.g., ENDO-AID) into its colonoscopy platforms. Broad incumbent that can bundle AI imaging with hardware, representing a structural threat to standalone CADe software players like Wision.
- Fujifilm: Major endoscopy and medical imaging OEM increasingly incorporating AI features into its colonoscopy and pathology workflows. Broad incumbent competitor whose installed base of endoscopes and pathology scanners gives it distribution leverage against standalone AI vendors like Wision.
Emerging players
- Proscia: Digital pathology platform company offering AI-powered image analysis alongside its Concentriq pathology workflow software. Overlaps with Wision's PathoCruz at the intersection of AI image analysis and pathology lab workflow.
- Owkin: AI biotech company applying machine learning to pathology and clinical data across multiple oncology indications. Adjacent peer in medical imaging AI with overlapping pathology applications.
- Tencent Miying: China-based medical imaging AI platform from Tencent covering endoscopy, pathology, and radiology applications. Direct regional competitor in China with overlapping GI endoscopy and digital pathology capabilities.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks7 records
Key highlights6 records
Customer concentration
Wision A.I. social profiles
Digital presenceWision A.I. compliance and trust
Trust signalCompliance3 records
Wision A.I. financial estimates
Financial estimateRevenue estimate
Valuation estimate
Wision A.I. leadership team
Management profileNumber of profiles
Profiles2 records
Wision A.I. funding detail
Funding detailFunding overview
Funding rounds2 records
Investors1 record
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Wision A.I. M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Wision A.I.
What does Wision A.I. do?
Wision A.I. develops and sells regulatory-cleared Computer-Aided Diagnosis (CAD) software for clinical optical medical imaging. Its core products—EndoScreener for real-time AI-assisted gastrointestinal endoscopy and colonoscopy, and PathoCruz for cancer region localization in whole slide histopathology images (plus the PathoCruz 3D reconstruction module)—are built on deep learning algorithms optimized for small datasets and are licensed to hospitals, endoscopy centers, and pathology laboratories.
Is Wision A.I. a public or private company?
Wision A.I. is a private company. It is classified as venture growth investor backed and is currently operating.
When was Wision A.I. founded?
Wision A.I. was founded in 2016. It employs 11 to 50 people.
Where is Wision A.I. based?
Wision A.I. is headquartered in Shanghai, China, in the Asia region.
How does Wision A.I. make money?
One revenue line is on record: medical Device Software Licensing.
Who are Wision A.I.'s main competitors?
Direct peers on record are Iterative Health, Cosmo Pharmaceuticals, Paige.AI and Ibex Medical Analytics. Broad incumbents are Medtronic (GI Genius), Olympus and Fujifilm. Emerging players are Proscia, Owkin and Tencent Miying.
Does Wision A.I. have an API?
No public API is recorded for Wision A.I..
What industry is Wision A.I. in?
Wision A.I.'s product category is Medical Imaging AI Software. Its primary akta.pro industry code is HDAAAEAH, Medical Imaging AI, with a secondary code of HLAHABAJ, Radiology AI, CAD & Advanced Visualization Software. Its NAICS code is 3345 and its SIC code is 3841.